RGMb Inhibitors
RGMb inhibitors belong to a class of chemical compounds specifically designed to target and modulate the activity of the Repulsive Guidance Molecule b (RGMb) protein. RGMb is a member of the RGM protein family, which includes RGMa and RGMc. These proteins play diverse roles in various biological processes, including neuronal development, axonal guidance, iron metabolism, and tissue repair. RGMb, in particular, has garnered attention for its involvement in neural development and the regulation of axonal growth during embryogenesis and in adult tissues. Inhibitors designed to target RGMb are primarily employed in molecular and cellular biology research to investigate the functional properties and regulatory mechanisms associated with this protein.
The development of RGMb inhibitors involves a multidisciplinary approach, including biochemical, biophysical, and structural techniques, aimed at identifying or designing molecules that can selectively interact with RGMb and modulate its activity. By inhibiting RGMb, these compounds can potentially disrupt its functions in axonal guidance and neuronal development, affecting processes such as axon pathfinding and tissue regeneration. Researchers use RGMb inhibitors to explore the intricate roles played by RGMb in cellular processes, attempting to unravel its contributions to neuronal wiring and neural circuit formation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Inhibits BMP signaling by targeting the BMP type I receptors ALK2, ALK3, and ALK6, which may lead to decreased RGMb expression as part of the downstream effect. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
A selective BMP type I receptor kinase inhibitor, which potentially downregulates BMP signaling and could indirectly inhibit RGMb expression. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
Another BMP receptor inhibitor that may reduce RGMb expression by altering BMP-mediated signaling pathways that regulate RGMb gene transcription. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
Inhibits the TGF-β type I receptor ALK5 and may affect RGMb expression by modifying BMP/TGF-β signaling crosstalk. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
As a selective inhibitor of TGF-β receptors ALK4, ALK5, and ALK7, its action may indirectly influence RGMb expression. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
Targeting TGF-β receptor kinases, this compound might indirectly inhibit RGMb expression through the TGF-β signaling pathway. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
An inhibitor of TGF-β receptor I, which may affect RGMb gene expression indirectly by modulating the TGF-β signaling associated with RGMb. | ||||||
Thiazovivin | 1226056-71-8 | sc-361380 sc-361380A | 10 mg 25 mg | $284.00 $634.00 | 15 | |
A ROCK inhibitor, it may influence the actin cytoskeleton and cellular processes that could be upstream of RGMb expression regulation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Another ROCK inhibitor, which may have indirect effects on RGMb expression by affecting cytoskeletal dynamics and related signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As a JNK inhibitor, it could modulate AP-1 activity and thereby potentially influence the transcription of genes like RGMb. | ||||||